Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation

Thrombosis Research

Volumn 117, Issue 3, 2006, Pages 235-240

  Coll Vinent, Blanca ^a   Monteagudo, Joan ^a   Miró, Òscar ^a   Luis Marín, José ^a   Nava, Santiago ^a   Scalise, Andrea ^a   Sánchez, Miquel ^a   Bragulat, Ernest ^a   Sitges, Marta ^a   Brugada, Josep ^a   Mont, Lluís ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Atrial fibrillation; Cardioversion; Endothelium

Indexed keywords

VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINUS RHYTHM; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; ANTIGENS; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; ELECTRIC COUNTERSHOCK; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 29244462828     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.02.013     Document Type: Article

References (27)

1. W.B. Kannel, P.A. Wolf, E.J. Benjamin, and D. Levy Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates Am J Cardiol 82 1998 2N 9N
2. S.S. Chugh, J.L. Blackshear, W.K. Shen, S.C. Hammill, and B.J. Gersh Epidemiology and natural history of atrial fibrillation: clinical implications J Am Coll Cardiol 37 2001 371 378
3. R.G. Hart, and J.L. Halperin Atrial fibrillation and stroke: concepts and controversies Stroke 32 2001 803 808
4. A.Z. Arnold, M.J. Mick, R.P. Mazurek, F.D. Loop, and R.G. Trohman Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J Am Coll Cardiol 19 1992 851 855
5. R.A. Grimm, D.Y. Leung, I.W. Black, W.J. Stewart, J.D. Thomas, and A.L. Klein Left atrial appendage "stunning" after spontaneous cardioversion at atrial fibrillation demonstrated by transesophageal Doppler echocardiography Am Heart J 130 1995 174 176
6. W.J. Manning, D.I. Silverman, S.E. Katz, M.F. Riley, P.L. Come, and R.M. Doherty Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation J Am Coll Cardiol 23 1994 1535 1540
7. E.G. Daoud, P. Marcovitz, B.P. Knight, P. Bradley, R. Goyal, and K.C. Man Short term effect of atrial fibrillation on atrial contractile function in humans Circulation 99 1999 3024 3027
8. R.A. Grimm, W.J. Stewart, J.D. Maloney, G.I. Cohen, G.L. Pearce, and E.E. Salcedo Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography J Am Coll Cardiol 22 1993 1359 1366
9. A.Y. Chong, A.D. Blann, and G.Y. Lip Assessment of endothelial damage and dysfunction: observations in relation to heart failure QJM 96 2003 253 267
10. N.M. AlSaady, and M. Sopher Prothrombotic markers in atrial fibrillation: what is new? Eur Heart J 22 2001 1635 1639
11. E.J. Favaloro Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder Best Pract Res Clin Haematol 14 2001 299 319
12. A.D. Blann, and M.A. Waite Von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis Coron Artery Dis 7 1996 143 147
13. M. Rabinovitch, M. Andrew, H. Thom, G.A. Trusler, W.G. Williams, and R.D. Rowe Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects Circulation 76 1987 1043 1052
14. W.F. Penny, M. Weinstein, E.W. Salzman, and J.A. Ware Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics Circulation 83 1991 1630 1636
15. C.R. Gibbs, A.D. Blann, R.D. Watson, and G.Y. Lip Abnormalities of hemorheological, endothelial and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin converting enzyme inhibitor and beta-blocker therapy Circulation 103 2001 1746 1751
16. G.Y.H. Lip, G.D. Lowe, A. Rumley, and F.G. Dunn Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin therapy Br Heart J 73 1995 527 533
17. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Association Task Force on Practice Guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences. Circulation 2001; 104:2118-2150.
18. P.J. Murdock, B.J. Woodhams, K.B. Matthews, K.J. Pasi, and A.H. Goodall von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use Thromb Haemost 78 1997 1272 1277
19. J. Monteagudo, A. Pereira, S. Roig, J.C. Reverter, A. Ordinas, and R. Castillo Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome Am J Hematol 33 1990 46 49
20. L. Oltrona, M. Broccolino, P. Merlini, A. Spinola, A. Pezzano, and P. Mannucci Activation of the haemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation Circulation 95 1997 2003 2006
21. G.Y. Lip, A. Rumley, F.G. Dunn, and G.D. Lowe Plasma fibrinogen and fibrin D-dimer levels in atrial fibrillation: effect of cardioversion to sinus rhythm Int J Cardiol 51 1995 245 253
22. R.M. Heppell, K.E. Berkin, J.M. McLenachan, and J.A. Davies Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation Heart 77 1997 407 411
23. K. Kumagai, M. Fucuchi, J. Ohta, S. Baba, K. Oda, and H. Akimoto Expression of the von Willebrand factor in atrial endocardium is increased in atrial fibrillation depending on the extent of structural remodeling Circ J 68 4 2004 321 327
24. D.S.G. Conway, L.A. Pearce, B.S.P. Chin, R.G. Hart, and G.Y.H. Lip Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation Circulation 107 2003 3141 3145
25. H. Sohara, S. Amitani, M. Kurose, and M. Kenkichi Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation J Am Coll Cardiol 29 1997 106 112
26. F.L. Li-Saw-Hee, A.D. Blann, D. Gurney, and G.Y. Lip Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function Eur Heart J 22 2001 1741 1747
27. N. Takahashi, A. Seki, K. Imataka, and J. Fujii Clinical features of paroxysmal atrial fibrillation: an observation of 94 patients Jpn Heart J 22 1981 143 149